EXOME: Biotech • Healthcare • Life Sciences

Europe
BioNTech’s mRNA COVID-19 Vaccine Shows Early Signs of Sparking Immunity

Boston
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
New York
FDA Says “No” to Intercept Pharma’s NASH Drug, Asks for More Data
National
New Xconomy Special Report: Biopharma and Tech Innovators Summer 2020

1.
MEI Pharma, Helsinn Scuttle Cancer Drug Trial After Miss on Efficacy | San Diego
2.
Moderna: Speed of COVID 19 Vaccine Hinges On Enrolling Right Patients | National
3.
Data Quantity, Complexity Drives Use of AI in Drug Discovery and Testing | San Francisco
4.
Annexon Adds On $100M to Advance Antibodies to Treat Neurodegeneration | San Francisco
5.
BioNTech’s mRNA COVID-19 Vaccine Shows Early Signs of Sparking Immunity | Europe
6.
Amylyx Adds $30M to Press On With Neuro Drug for ALS, Alzheimer’s | Boston

Learn about the Xconomists →

Alexis Peyroles

Creating Consistent Value in Biotech Without Diluting Stakeholders

Andy Smith

Lax Approval Requirements Yield Blockbusters That Don’t Work

More Opinion, Insight, and Analysis ›

Data Quantity, Complexity Drives Use of AI in Drug Discovery and Testing

$100M

Annexon

Mereo BioPharma Appoints John Lewicki Chief Scientific Officer

Akcea Therapeutics Names Tracy Palmer Berns Chief Compliance Officer

Bolt Bio Adds $93.5M to Move Ahead Immune-Stimulating Cancer Drugs
Sarah de Crescenzo | San Francisco
Chiesi Licenses Bioasis Tech to Tackle Brain Symptoms of Rare Diseases
Sarah de Crescenzo | Boston
Ultragenyx Pharma Wins FDA’s First Drug Nod for Rare Metabolic Disorder
Frank Vinluan | San Francisco
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
Frank Vinluan | Boston
Code for Cures: Life Sciences Thrives on San Francisco’s Software Heritage
Sarah de Crescenzo | San Francisco
Roche Gets FDA OK for Injectable Version of Breast Cancer Drug
Sarah de Crescenzo | San Diego
FDA Again Dings Heron’s Opioid Alternative Over “Nonclinical Issues”
Sarah de Crescenzo | San Diego
FDA Says “No” to Intercept Pharma’s NASH Drug, Asks for More Data
Frank Vinluan | New York
New Xconomy Special Report: Biopharma and Tech Innovators Summer 2020
Editors | National

Read More Posts ›

Underwriters and Partners

Xconomy Insight

Xconomy Insight · Special Report
How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook
Insights, wisdom, and inspiration on what it takes

From Our Editors · Podcast
Xcelerating Life Sciences San Diego: The Highlights Podcast
Learn what's fueling San Diego's biotech investment and partnership opportunities

Sponsored · Whitepaper
IBM Watson Health Data in Action – Epidemiology Studies
With data from IBM Watson Health, epidemiologists can describe treatment patterns, persistence & adherence to therapy
IBM Watson

Xconomy on Demand

We offer a number of ways to subscribe for free!